New Products
1. Grand Pharma’s rare disease drug Carglutamic acid dispersible tablets issued with drug registration certificate
In September 2023, Carglutamic acid dispersible tablets (Anvid@), independently developed by Grand Pharma for the treatment of hyperammonemia caused by N-acetylglutamic acid synthetase (NAGS) deficiency, isovaleric acidemia (IVA), methylmalonic acidemia (MMA), or propionic acidemia (PA) in adults or children, was awarded the Certificate of Drug Registration by the State Drug Administration (SDA). Hypergammaglobulinemia is a clinically critical condition in which excessive blood gas concentration is highly toxic to the nervous system and even causes irreversible damage to the brain. Carglutamic acid dispersible tablets can rapidly reduce blood ammonia levels, and have been marketed in many countries and regions, including Europe and the United States, and have been included in the U.S. EDA’s Orphan Drug List. The launch of Grand Pharma’s Carglutamic Acid Dispersible Tablets in China not only provides a safe and effective means of clinical treatment, but is also expected to reduce the medical burden of patients with congenital hereditary hypergammaglobulinemia.
2. Grand Pharma’s Ophthalmic product Travoprost Eye Drops approved for marketing
In October 2023, 诺明® (Nuoming) Travoprost Eye Drops, independently developed by Yuanda Pharmaceutical, was approved for marketing. Travoprost Eye Drops can reduce the intraocular pressure of adult patients with open-angle glaucoma or high intraocular pressure, and is the first-line drug for the treatment of glaucoma. Glaucoma is often called the “invisible killer” of human blindness, and it is one of the major blinding eye diseases in ophthalmology with a high prevalence of common and frequent diseases. Travoprost Eye Drops is a highly selective and high affinity prostaglandin FP receptor full agonist with its potency and high safety for glaucoma patients.
3. Grand Pharma’ Innovative Liquid Embolic System LavaTM Commercialized in the United States
In October 2023, BlackSwan Vascular, Inc., a subsidiary of Grand Pharma, commercialized LavaTM, the first and only FDA-approved innovative liquid embolic system for the treatment of peripheral vascular arterial hemorrhage in the U.S. LavaTM is easy to use and can be prepared in as little as three minutes. LavaTM is easy to use and takes only three minutes to prepare, saving physicians’ preparation time in emergency situations and increasing the likelihood of patient survival. The successful commercialization of this product not only provides a new treatment option for patients with peripheral arterial hemorrhage in the U.S., but also marks a major milestone in Grand Pharma’s internationalization strategy.
Company News
1. Guo Yuanqiang, secretary of Wuhan Municipal Party Committee, investigated Grand Pharma
On October 17, 2023, Guo Yuanqiang, member of the Standing Committee of Hubei Provincial Committee and Secretary of Wuhan Municipal Party Committee, researched Grand Pharma during his supervision of the second batch of theme education in Qiaokou District. He inspected the innovative products independently researched and developed by the enterprise, and learned in detail about the construction of the Huantongji Great Health Science and Technology Industrial Zone and the development of the enterprise. Tang Weikun, president of Grand Pharma, introduced the development of innovative business of Grand Pharma. Guo Yuanqiang fully affirmed the idea of innovation and development of Grand Pharma, and emphasized that it is necessary to strengthen the status of the main body of enterprise science and technology innovation, increase investment in research and development, aim at the direction of biopharmaceuticals, small molecule innovative drugs, high-end generic drugs, etc., carry out technological research and development of new products, and promote Wuhan’s life and health industry to extend the industrial chain, enhance the value chain, and accelerate the growth of the pillar industry.
2. Grand Pharma launches 2023 Echelon Talent Development Program
In September 2023, Grand Pharma’s 2023 Echelon Talent Development Program started in Wuhan, China. 195 trainees exercised their physical fitness and will, brought their friendship closer to each other, and demonstrated their team cohesion and executive power through military training, sharing of corporate culture, learning of cadre management, hiking and dragon-boat racing. Talents are the most core assets of Grand Pharma, and the practice of the Group’s development has proved that cultivating Grand Pharma’s own cadres is the key to the perpetuation of Grand Pharma’s business and the passing on of the flame to the next generation. Grand Pharma has always adhered to the mechanism of “endogenous talent supply”, and the goal of echelon talent cultivation is to enhance the fighting force of employees, build an efficient team, and help realize the company’s strategic goals.
3. Beijing Grand Johamu Pharmaceutical presented Enerzair® and Atectura® at 2023 Annual Congress of Chinese Thoracic Society
On September 4, 2023, the 2023 Annual Congress of Chinese Thoracic Society was grandly opened in the mountain city of Chongqing, Beijing Grand Johamu Pharmaceutical, from the respiratory field of the product pipeline layout, with the global innovative products Enerzair® and Atectura® appeared at the meeting, and held a satellite conference on the theme of New Options for Optimizing Asthma Management from GINA2023. The conference was well attended, and the participating experts highly recognized the launch of the two products. In the exhibition area of the conference, the booth of Beijing Grand Johamu Pharmaceutical also attracted the eyes of many physicians, and there was an endless stream of scholars visiting and consulting. A number of well-known experts came to the booth and highly praised Beijing Grand Johamu Pharmaceutical for its excellent contribution in the field of respiratory diseases.
4. Grand Pharma appears at the 27th Congress of Chinese Ophthalmological Society
On September 25, 2023, the 27th Congress of Chinese Ophthalmological Society was held at Changsha International Convention and Exhibition Center and Changsha International Conference Center. Grand Pharma, together with its member companies Xi’an Beilin Pharmaceutical, EBE Pharmaceutical and Tianjin Jingming New Technological Development, presented a variety of its main products, including ophthalmic proprietary medicines, ophthalmic chemicals and ophthalmic instruments and consumables, at the ophthalmology academic event.
At the exhibition, Grand Pharma focused on the display of ophthalmic proprietary Chinese medicine products: 和血明目 (Hexuemingmu) Tablets, 复明 (Fuming) Tablets, 枸明 (Qiming) Capsules, Mingmu profane pill, etc., ophthalmic chemical products: 瑞珠® (Ruizhu) Polyvinyl Alcohol Eye Drops, 诺亮® (Nuoliang) Toxicarbamate Eye Drops, etc., ophthalmic equipment and consumables: 晶明® (Jingming) Tear Fluid Detection Filter Strips, 安视美® (Anshimei) Soft Hydrophilic Contact Lenses, etc.. Concentrate on the company’s multi-product combination of treatment of ophthalmic ocular surface, fundus and other parts of the disease diagnosis and treatment of clinical concepts and advantages.
5. HeartLightX3 Balloon Laser Ablation successfully performed Again at Ruijin Hainan Hospital
In September 2023, the HeartLightx3 balloon laser ablation procedure was successfully performed again on a patient with atrial fibrillation by Prof. Denning Liao of the Department of Cardiology of Shanghai Changzheng Hospital with the surgical team in cooperation with the team of Ruijin Hospital attached to Shanghai Jiaotong University School of Medicine, supported by Prof. Li-Qun Wu of the Department of Cardiology of the Hospital HeartLight X3 Balloon Laser System, as the world’s only laser ablation system that combines the cardiac As the world’s only laser ablation system that combines an optical endoscope and a super-compliant balloon, its first and second generation systems have completed more than 18,000 clinical treatments worldwide, and have a high degree of applicability.
In order to ensure the smooth operation, Grand Pharma sent a technical team to train the surgical team before the operation. As the HeartLightX3 system is simple and intuitive to operate, the surgical team mastered the use of the system before the operation, and the operation was finally successful. After the operation, the patient was in good condition and had no adverse reactions.
6. Grand Pharma adjustable stent-based embolization device clinical study results revealed at the 15th World Stroke Conference
On October 10, 2023, the 15th World Stroke Congress (WSC) was held in Toronto, Canada. In the Translational Research on Endovascular Treatment of Acute Stroke section of the Congress, Prof. Peng Ya, the principal investigator (PI) of the clinical trial, made a presentation on “90-day clinical results of a prospective, multicenter, randomized, non-inferiority study of a novel adjustable stent and Solitaire FR”. Prof. Peng Ya reported the clinical registration data of Grand Pharma’s new woven adjustable stent-type thrombus extraction device KEYNEUTLUCI® (鸬鹚), releasing to the world the excellent results of the registration clinical trial, providing strong evidence-based evidence for the clinical safety and efficacy of this product for the later stage of the domestic market application.
Clinical Progress
1. Ryaltris® Compound Nasal Spray completes domestic phase III clinical study and successfully achieves primary endpoints
In September 2023, the Phase II clinical study (GSP 301-308) in China of Ryaltris® Compounded Nasal Spray (GSP 301NS), a global innovation of Grand Pharma, for the treatment of Seasonal Allergic Rhinitis (SAR) in patients 12 years of age and older, has been completed and has successfully met its primary endpoint.
GSP 301NS is a novel antihistamine-corticosteroid combination nasal spray for the treatment of SAR in adults and adolescents, and as a combination, GSP 301NS offers a new treatment option for patients with SAR by providing a more convenient treatment modality and improving patient compliance.
2. GPN00833 phase III clinical trial in China completes enrollment of first patient for dosing
In October 2023, the domestic phase III clinical trial of GPNO0833, a hormone nano-mixed eye drop used for anti-inflammatory and analgesic purposes by Grand Pharma, was completed with the first case of patient enrollment and dosing. The main active ingredient of GPN00833, clobetasol propionate, has highly effective local anti-inflammatory activity and strong capillary constriction. The unique nanoformulation process of the product effectively solves the low bioavailability and safety risks caused by the low water solubility of hormone products. This phase III clinical study enrolls 252 patients who have undergone cataract surgery, and aims to evaluate the efficacy and safety of GPN00833 in the treatment of post-cataract surgery inflammation and pain in the Chinese patients.
Media Focus
1. New Weekly reports on liver cancer patient’s tearful story of twisted quest for treatment that turned out to be a miracle.
On September 20, 2023, New Weekly published the article “Life after Cancer: Shimmering Light Shines into the Cracks of Life, Gaming the Future with Hope (癌后人生:微光照进生命的裂缝，用希望博弈未来)” reporting the stories of Shen Chao, a patient with advanced liver cancer, and Zhou Sen (both pseudonyms), a patient with colorectal cancer accompanied by liver metastases. Dr. Zhang Lin said, “The development of new technologies must maximize the benefits for patients. To make a technology truly benefit patients, we first need to find the most suitable patients, then refine and standardize the operation to complete the surgery, as well as provide the most perfect follow-up treatment plan and follow-up.” As doctors and patients expect, Yttrium-90 [90Y] is being more widely used in clinical settings, giving more people hope to live.
2. Southern Weekly reports on liver cancer patient stories, several patients regained their lives with Yttrium 90 [90Y]
On September 27, 2023, Southern Weekly published an article titled “Liver Patient’s Monologue: More Important Thing Than ‘Staying Alive’ (肝患者独白:比“活下去”更重要的事)”, which reported the stories of Lao Chen and Ah Qing (both pseudonyms), both of whom are suffering from liver cancer. Both patients were in dubious or hard-to-treat cases, unable to directly remove liver tumors, and were eager to find new treatment options. Professor Liu Hui, Vice President of the Third Affiliated Hospital of the Naval Military Medical University, analyzed the patient’s situation and gave the recommendation of using Yttrium-90 [90Y] internal radiation therapy, and answered the patients’ questions about the unique advantages of internal radiation therapy. Doctors said that since the successful implementation of the first case of licensed access to the Yttrium-90 [90Y] resin microspheres for the treatment of liver cancer surgery in China, the emergence of Yttrium-90 [90Y] has added a new technological means for the treatment of liver cancer, and also opened up a new dimension in the diagnosis and treatment of late-stage liver cancer.
3. China Science Communication issues an article on new liver cancer treatment with in-depth analysis of Yttrium-90 [90Y] Treatment Principles
On October 8, 2023, China Science Communication published the article “Will this therapy become a new hope for liver cancer patients? (这种疗法，会成为肝癌患者的新希望吗？)”. The article is based on patients’ real-life experiences with Yttrium-90 [90Y] treatment, and analyzes in detail the principles, modes of action, and safety of Yttrium-90 [90Y] treatment for cancer, popularizing this brand-new treatment for the general public.
4. Little China Media Group Mobile releases “The Reunion Dinner We Didn’t Dare Think About” Yttrium-90 [90Y] saving lives and raising family reunions
On September 28, 2023, Little China Media Group Mobile (小央视频) released the heartwarming video “The Reunion Dinner We Didn’t Dare Think About (不敢想的团圆饭)”, which tells the true story of Mr. Zeng, a patient with advanced liver cancer, who was originally diagnosed when the doctor had already declared that the patient had only a few months left to live. For the sake of his lover, his children, and his entire family, Mr. Zeng made up his mind not to give up, and ran around to seek medical treatment. Eventually, he was successfully treated with Yttrium-90 [90Y] resin microsphere therapy. During the Mid-Autumn Festival, Mr. Zeng and his family were all smiles. After his physical recovery, he was finally back to his old happy days.
